LENZ Therapeutics annual free cash flow
2020
2021
2022
2023
2024
2025
LENZ Therapeutics Free Cash Flow (FCF) History (LENZ)
LENZ Therapeutics reported −$70.0M in free cash flow for fiscal 2025, a decrease of $10.1M from the previous fiscal year, with a free cash flow margin of −366.71%.
View full LENZ Therapeutics company overviewLENZ Therapeutics free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$70.0M | −$10.1M | — | −366.71% |
| 2024 | 2024-12-31 | −$59.9M | $551,000 | — | — |
| 2023 | 2023-12-31 | −$60.4M | $34.2M | — | — |
| 2022 | 2022-12-31 | −$94.6M | −$36.0M | — | — |
| 2021 | 2021-12-31 | −$58.6M | −$48.3M | — | — |
| 2020 | 2020-12-31 | −$10.3M | — | — | — |
LENZ Therapeutics quarterly free cash flow
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$38.7M | −$27.0M | — | −705.96% |
| Q1 2026 | 2026-03-31 | −$33.6M | −$17.4M | — | −1767.49% |
| Q4 2025 | 2025-12-31 | −$33.1M | −$23.8M | — | −2082.05% |
| Q3 2025 | 2025-09-30 | −$9.0M | $1.7M | — | −72.22% |
| Q2 2025 | 2025-06-30 | −$11.7M | $4.2M | — | −234.96% |
| Q1 2025 | 2025-03-31 | −$16.2M | $7.8M | — | — |
| Q4 2024 | 2024-12-31 | −$9.2M | $11.7M | — | — |
| Q3 2024 | 2024-09-30 | −$10.8M | $2.3M | — | — |
| Q2 2024 | 2024-06-30 | −$15.9M | −$2.4M | — | — |
| Q1 2024 | 2024-03-31 | −$23.9M | −$11.1M | — | — |
| Q4 2023 | 2023-12-31 | −$21.0M | $2.5M | — | — |
| Q3 2023 | 2023-09-30 | −$13.1M | $10.0M | — | — |
| Q2 2023 | 2023-06-30 | −$13.5M | $9.9M | — | — |
| Q1 2023 | 2023-03-31 | −$12.8M | $11.7M | — | — |
| Q4 2022 | 2022-12-31 | −$23.4M | −$6.9M | — | — |
| Q3 2022 | 2022-09-30 | −$23.1M | −$4.1M | — | — |
| Q2 2022 | 2022-06-30 | −$23.5M | −$8.9M | — | — |
| Q1 2022 | 2022-03-31 | −$24.5M | −$16.1M | — | — |
| Q4 2021 | 2021-12-31 | −$16.6M | −$13.5M | — | — |
| Q3 2021 | 2021-09-30 | −$19.1M | — | — | — |
| Q2 2021 | 2021-06-30 | −$14.5M | — | — | — |
| Q1 2021 | 2021-03-31 | −$8.4M | — | — | — |
| Q3 2020 | 2020-09-30 | −$3.0M | — | — | — |
LENZ Therapeutics free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from −$10.3M to −$70.0M, a net decrease of $59.7M. LENZ Therapeutics's latest reported quarter, Q2 2026, generated −$38.7M in free cash flow, a decrease of $27.0M year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review LENZ Therapeutics filings at SEC.gov ↗